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Introduction {#jdi12367-sec-0005}
============

Type 2 diabetes is a progressive disorder, characterized by insulin resistance at peripheral tissues and relative insulin secretion deficiency[1](#jdi12367-bib-0001){ref-type="ref"}. As the disease progresses, monotherapy and then combination therapy might become necessary as an add‐on to diet and exercise; glucagon‐like peptide 1 (GLP‐1) receptor agonists, oral antidiabetic drugs (OADs) and/or insulin are the current intensification options[1](#jdi12367-bib-0001){ref-type="ref"}, [2](#jdi12367-bib-0002){ref-type="ref"}.

GLP‐1 is a hormone that stimulates glucose‐dependent insulin secretion and suppresses glucagon secretion[3](#jdi12367-bib-0003){ref-type="ref"}. However, endogenous GLP‐1 has a very short half‐life (1.5 min)[3](#jdi12367-bib-0003){ref-type="ref"}, which limits its therapeutic value. Liraglutide is an analog of human GLP‐1 with 97% homology to the endogenous protein[4](#jdi12367-bib-0004){ref-type="ref"} and a half‐life of 13 h, resulting in a pharmacokinetic profile that is suitable for once‐daily dosing[5](#jdi12367-bib-0005){ref-type="ref"}. The safety and efficacy of liraglutide have been established through a series of international phase 3 trials \[Liraglutide Effect and Action in Diabetes (LEAD)\][6](#jdi12367-bib-0006){ref-type="ref"}, [7](#jdi12367-bib-0007){ref-type="ref"}, [8](#jdi12367-bib-0008){ref-type="ref"}, [9](#jdi12367-bib-0009){ref-type="ref"}, [10](#jdi12367-bib-0010){ref-type="ref"}, [11](#jdi12367-bib-0011){ref-type="ref"}, [12](#jdi12367-bib-0012){ref-type="ref"}, [13](#jdi12367-bib-0013){ref-type="ref"}, [14](#jdi12367-bib-0014){ref-type="ref"}, as well as two trials in Japan[15](#jdi12367-bib-0015){ref-type="ref"}, [16](#jdi12367-bib-0016){ref-type="ref"}, [17](#jdi12367-bib-0017){ref-type="ref"}, [18](#jdi12367-bib-0018){ref-type="ref"}.

Sulfonylureas (SUs) are the most commonly used OADs in Japan, and the efficacy and safety of liraglutide in combination with a SU has been established in Japanese patients with type 2 diabetes[15](#jdi12367-bib-0015){ref-type="ref"}. No other liraglutide combinations have been investigated in phase 3 trials in Japanese patients. However, such trials have been carried out globally, and showed that liraglutide is effective and well tolerated in combination with one or two OADs[7](#jdi12367-bib-0007){ref-type="ref"}, [9](#jdi12367-bib-0009){ref-type="ref"}, [10](#jdi12367-bib-0010){ref-type="ref"}.

In July 2010, the Japanese Ministry of Health, Labor and Welfare issued a guideline stating that investigational drugs confirmed to be useful in clinical studies that conformed to the guideline could receive a broad indication for 'type 2 diabetes'[19](#jdi12367-bib-0019){ref-type="ref"}. Any product having this indication can be used concomitantly with any other approved antihyperglycemic agent that has a different mechanism of action. Thus, the present study was initiated with the objective of assessing the safety and efficacy of liraglutide in combination with OAD options available at the time of designing the trial (glinide, metformin, α‐glucosidase inhibitor or thiazolidinedione), vs a combination of two OADs, in patients with type 2 diabetes insufficiently controlled with OAD monotherapy. As stipulated in the Japanese Ministry of Health, Labor and Welfare guideline, the primary end‐point of the study was safety, and the study duration was set at 1 year[19](#jdi12367-bib-0019){ref-type="ref"}. Glinides, metformin, α‐glucosidase inhibitors or thiazolidinediones were selected as the allowed OADs for co‐administration with liraglutide. SUs and dipeptidyl peptidase‐4 (DPP‐4) inhibitors were not included, because concomitant use of liraglutide and SUs was already approved in Japan, and because DPP‐4 inhibitors affect the same incretin pathway as liraglutide[20](#jdi12367-bib-0020){ref-type="ref"}.

Materials and Methods {#jdi12367-sec-0006}
=====================

Trial Design and Interventions {#jdi12367-sec-0007}
------------------------------

This was a 52‐week, open‐label, randomized, parallel‐group trial with an active control (combination therapy with two OADs), designed to evaluate the safety and efficacy of liraglutide in combination with an OAD (glinide, metformin, α‐glucosidase inhibitor or thiazolidinedione) in patients with type 2 diabetes. It was carried out at 36 sites in Japan between January 2012 and April 2013.

Patients treated previously with one OAD were randomized to liraglutide (0.9 mg/day) add‐on therapy (liraglutide group) or to add‐on therapy with another OAD (additional OAD group) in a 2:1 ratio, using an Interactive Voice/Web Response Service. At randomization, patients were stratified according to the type of pretrial OAD. It was required that the total daily dose and type of pretrial drug should have remained unchanged for ≥8 weeks before screening.

Patients received their pretrial OAD in combination with liraglutide, or their pretrial OAD in combination with an additional OAD with a mechanism of action different from the pretrial OAD (within the approved combination‐use labeling in Japan). The type, dosage and administration of the additional OAD were chosen by the investigator within approved labeling. The additional OAD used could be a DPP‐4 inhibitor, SU, glinide, metformin, α‐glucosidase inhibitor or thiazolidinedione.

Patients in the liraglutide group injected themselves subcutaneously with liraglutide once daily. The starting dose was 0.3 mg/day; after 1 week, this was escalated to 0.6 mg/day, and after a further week, to 0.9 mg/day.

Participants {#jdi12367-sec-0008}
------------

The study included male and female Japanese patients aged ≥20 years, with type 2 diabetes for at least 6 months, glycosylated hemoglobin (HbA1c) levels of 7.0--10.0% (both inclusive) and body mass index of \<40.0 kg/m^2^. All participants were receiving treatment with OAD monotherapy (glinide, metformin, α‐glucosidase inhibitor or thiazolidinedione) within approved Japanese labeling, as well as diet and exercise therapy. Patients were excluded if they had used any of the following within the past 12 weeks: a GLP‐1 receptor agonist, a DPP‐4 inhibitor or insulin. Other exclusion criteria included personal history of non‐familial medullary thyroid carcinoma, family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma, malignant tumor (either known or previous and strongly suspected of recurrence), history of chronic pancreatitis or idiopathic acute pancreatitis, calcitonin ≥160 pg/mL (radioimmunoassay‐2 method), or contraindications to liraglutide or any of the OADs (according to Japanese labeling). Patients with recurrent severe hypoglycemia, hypoglycemia unawareness or hospitalization for diabetic ketoacidosis during the previous 6 months were also excluded.

Informed consent was obtained in advance of any trial‐related activities. The protocol was reviewed by the Japanese authority according to local regulations, and reviewed and approved by an institutional review board. The trial is registered with clinicaltrials.gov (NCT01512108) and the Japanese Clinical Trials Registry (JapicCTI‐121744), and was carried out in accordance with the Declaration of Helsinki[21](#jdi12367-bib-0021){ref-type="ref"} and the International Conference on Harmonization Good Clinical Practice[22](#jdi12367-bib-0022){ref-type="ref"}.

End‐Points and Assessments {#jdi12367-sec-0009}
--------------------------

The primary end‐point was the incidence of adverse events (AEs) during 52 weeks. The nature, severity and relationship to trial products of all AEs were recorded (relationship to trial product was judged by investigator). A treatment‐emergent AE was defined as an event with an onset date on or after the first day of exposure to randomized treatment (liraglutide or additional OAD) and no later than 7 days after the last day of randomized treatment.

Secondary safety end‐points included the number of hypoglycemic episodes during 52 weeks and changes from baseline in vital signs (blood pressure and pulse rate). Hypoglycemia was classified according to the American Diabetes Association definition (severe, documented symptomatic, asymptomatic, probable symptomatic and relative)[23](#jdi12367-bib-0023){ref-type="ref"} with the addition of a minor category. Minor hypoglycemia (symptomatic or asymptomatic) was defined as plasma glucose \<56 mg/dL (3.1 mmol/L) or blood glucose \<50 mg/dL (2.8 mmol/L). Collectively, severe and minor hypoglycemic episodes were referred to as "confirmed" hypoglycemic episodes.

Secondary efficacy end‐points were assessed after 52 weeks of treatment. These included change from baseline in HbA1c, change from baseline in fasting plasma glucose (FPG), patients achieving target HbA1c \<7.0%, change from baseline in bodyweight and change from baseline in β‐cell function \[homeostasis model assessment (HOMA)‐B, and proinsulin:insulin and proinsulin:C‐peptide ratios\]. Seven‐point self‐measured plasma glucose (SMPG) profiles were also assessed (change from baseline in mean plasma glucose and in mean prandial plasma glucose increment). Self‐monitoring of blood glucose (SMBG) was carried out with a glucose meter, and converted to plasma values (SMPG).

Statistical Analysis {#jdi12367-sec-0010}
--------------------

The necessary sample size (360 patients randomized 2:1 to receive either liraglutide 0.9 mg or additional OAD) was determined based on the requirements of the Japanese Ministry of Health, Labor and Welfare Guideline for Clinical Evaluation of Oral Hypoglycemic Agents[19](#jdi12367-bib-0019){ref-type="ref"}. Randomization was stratified according to the type of pretrial OAD, with a requirement for 90 patients (60 in the liraglutide 0.9 mg group and 30 in the additional OAD group) to be included in each OAD stratum. The number of patients was determined such that at least 50 patients would complete the 52‐week treatment with liraglutide 0.9 mg in combination with each OAD, assuming a dropout rate of 15%, in accordance with the guideline[19](#jdi12367-bib-0019){ref-type="ref"}.

The full analysis set included all randomized patients who received at least one dose of trial products; evaluation followed the intention‐to‐treat principle, with patients contributing 'as randomized'. The safety analysis set included all patients receiving at least one dose of trial product, with patients contributing 'as treated'. Analyses were based on full analysis set for efficacy end‐points and on the safety analysis set for safety end‐points. For all end‐points, the last observation carried forward approach was used for patients with at least one valid post‐baseline measurement.

For the primary end‐point (incidence of AEs), the number of patients experiencing an event, the percentage of patients with at least one event, the number of events and the event rate per 100 patient‐years of exposure (PYE) are presented.

For change from baseline in blood pressure and pulse rate after 52 weeks of treatment, 95% confidence intervals (CIs) for the mean difference (liraglutide group minus additional OAD group) were calculated based on an analysis of variance ([anova]{.smallcaps}) model, with treatment group and type of pretrial OAD as fixed effects, and the corresponding baseline value as a covariate. Secondary efficacy end‐points (except for patients achieving target HbA1c \<7.0%) were also analyzed using an [anova]{.smallcaps} model, with treatment group and type of pretrial OAD as fixed effects, and the corresponding baseline value as a covariate. The estimated mean differences with corresponding 95% CIs are provided together with the two‐sided *P*‐values. Observed end‐of‐treatment values are given as mean ± standard deviation. End‐points for β‐cell function were log‐transformed before analysis. For the analysis of patients achieving target HbA1c \<7.0%, a logistic regression model was used with treatment group and type of pretrial OAD as fixed effects, and HbA1c at baseline as a covariate. The estimated odds ratio with corresponding 95% CI is shown, together with the two‐sided *P*‐value.

Results {#jdi12367-sec-0011}
=======

Demographics {#jdi12367-sec-0012}
------------

A total of 363 patients were randomized, of whom three in the liraglutide group were withdrawn before being exposed to the trial product (Figure [1](#jdi12367-fig-0001){ref-type="fig"}). A total of 360 patients received at least one dose: 240 in the liraglutide group and 120 in the additional OAD group. The withdrawal rate was comparable between the two treatment groups (9.1% in the liraglutide group; 7.5% in the additional OAD group).

![Participant flow during the trial. ^†^Three patients in the liraglutide group were withdrawn after randomization, but before exposure to the trial product (consent withdrawal *n* = 1; randomization in error *n* = 1; non‐compliance *n* = 1). The remainder were withdrawn after exposure to at least one dose. OAD, oral antidiabetic drug.](JDI-7-076-g001){#jdi12367-fig-0001}

The number of patients withdrawing because of AEs was similar for both treatment groups \[nine patients (3.8%) and four patients (3.3%) for the liraglutide and placebo group, respectively\].

In general, the demographics and baseline characteristics were similar (Table [1](#jdi12367-tbl-0001){ref-type="table-wrap"}). In the additional OAD group, the OAD added after randomization was either a DPP‐4 inhibitor (*n* = 51), metformin (*n* = 30), α‐glucosidase inhibitor (*n* = 16), SU (*n* = 14), thiazolidinedione (*n* = 5) or glinide (*n* = 4).

###### 

Participant demographics and baseline characteristics

                                 Liraglutide (*n* = 240)   Additional OAD (*n* = 120)   Total (*n* = 360)
  ------------------------------ ------------------------- ---------------------------- -------------------
  Male, *n* (%)                  182 (75.8)                80 (66.7)                    262 (72.8)
  Age (years)                    59.6 (11.6)               59.2 (10.2)                  59.5 (11.1)
  Bodyweight (kg)                69.4 (14.2)               68.2 (13.6)                  69.0 (14.0)
  BMI (kg/m^2^)                  25.7 (4.2)                25.5 (3.7)                   25.7 (4.1)
  Duration of diabetes (years)   7.80 (5.77)               8.47 (6.55)                  8.02 (6.04)
  FPG (mg/dL)                    156 (29)                  161 (33)                     158 (30)
  HbA1c (%)                      8.1 (0.8)                 8.1 (0.8)                    8.1 (0.8)
  Pretrial OAD, *n* (%)                                                                 
  α‐GI                           63 (26.3)                 30 (25.0)                    93 (25.8)
  Glinide                        58 (24.2)                 31 (25.8)                    89 (24.7)
  Metformin                      61 (25.4)                 31 (25.8)                    92 (25.6)
  Thiazolidinedione              58 (24.2)                 28 (23.3)                    86 (23.9)

Data are mean (standard deviation) unless otherwise stated. α‐GI, α‐glucosidase inhibitor; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; OAD, oral antidiabetic drug.

John Wiley & Sons, Ltd

Safety {#jdi12367-sec-0013}
------

No new safety concerns were identified in either treatment group during the study. The primary end‐point was the incidence of AEs, and comparable proportions of patients reported AEs in the liraglutide (86.3%) and additional OAD (85.0%) groups (Table [2](#jdi12367-tbl-0002){ref-type="table-wrap"}). The majority of AEs were mild in severity. The overall AE rate was similar between the two groups (361 and 331 events per 100 PYE in the liraglutide and additional OAD groups, respectively; Table [2](#jdi12367-tbl-0002){ref-type="table-wrap"}). The relationship to the trial product was judged only for liraglutide, and most AEs were considered unlikely to be related by the investigator.

###### 

Summary of treatment‐emergent adverse events (safety analysis set)

                         Liraglutide (*n* = 240)   Additional OAD (*n* = 120)                            
  ---------------------- ------------------------- ---------------------------- ----- ------------ ----- -----
  All AEs                207 (86.3)                817                          361   102 (85.0)   380   331
  Serious AEs            11 (4.6)                  11                           5     10 (8.3)     10    9
  Severity                                                                                               
  Severe                 4 (1.7)                   5                            2     2 (1.7)      2     2
  Moderate               22 (9.2)                  31                           14    9 (7.5)      10    9
  Mild                   207 (86.3)                781                          345   102 (85.0)   368   321
  Nasopharyngitis        89 (37.1)                 135                          60    47 (39.2)    85    74
  Influenza              8 (3.3)                   8                            4     6 (5.0)      6     5
  Constipation           44 (18.3)                 48                           21    12 (10.0)    13    11
  Nausea                 31 (12.9)                 33                           15    4 (3.3)      4     3
  Diarrhea               20 (8.3)                  25                           11    9 (7.5)      10    9
  Abdominal discomfort   19 (7.9)                  21                           9     1 (0.8)      1     1
  Dental caries          7 (2.9)                   7                            3     6 (5.0)      6     5
  Diabetic retinopathy   21 (8.8)                  22                           10    16 (13.3)    16    14
  Cataract               8 (3.3)                   8                            4     8 (6.7)      8     7
  Headache               12 (5.0)                  14                           6     4 (3.3)      4     3
  Back pain              13 (5.4)                  14                           6     3 (2.5)      3     3

AE, adverse event; GI, gastrointestinal; OAD, oral antidiabetic drug; PYE, patient‐years of exposure.

John Wiley & Sons, Ltd

Gastrointestinal disorders appeared more common in the liraglutide group than in the additional OAD group (50.8% vs 34.2%, 89 vs 75 events per 100 PYE, respectively; Table [2](#jdi12367-tbl-0002){ref-type="table-wrap"}). The most frequently reported gastrointestinal AE in both treatment groups was constipation. Gastrointestinal AEs occurred most frequently within the first 4 weeks of the treatment period (data not shown), particularly in the liraglutide group, but during the remainder of the treatment period gastrointestinal AEs occurred sporadically in both groups, and no specific occurrence patterns were observed. Nasopharyngitis was the most frequently reported AE, when categorized according to preferred terms, and the rates and percentages of patients experiencing these events were similar in both groups (37.1 and 39.2% in the liraglutide and additional OAD groups, respectively).

Based on a predefined MedDRA PT search, a total of 15 injection‐site reactions were identified in 12 patients (5.0%) in the liraglutide group, but all of these events were non‐serious and mild in severity.

The incidence of serious AEs was low in both groups (five and nine events per 100 PYE in the liraglutide and additional OAD groups, respectively). A total of 13 patients were withdrawn from the trial owing to AEs, of whom nine were in the liraglutide group and four were in the additional OAD group. One death was reported in the liraglutide group: a malignant lung neoplasm that was diagnosed after 5 months of exposure to the trial product. This was considered unlikely to be related to the trial product by the investigator.

There were no reported events of pancreatitis or suspicion of pancreatitis. For both amylase and lipase, the mean values at baseline and after 52 weeks were within the reference ranges (37--125 U/L for amylase; 11--53 U/L for lipase). After 52 weeks of treatment, geometric mean amylase levels (68 U/L at baseline) appeared higher in the liraglutide group than in the additional OAD group (74.3 U/L vs 70.8 U/L, respectively). Similarly, geometric mean lipase levels (36 U/L at baseline) appeared higher with liraglutide than with additional OAD (49.3 U/L vs 37.6 U/L, respectively). Changes in calcitonin were small in both treatment groups, and no apparent differences were observed between groups.

Seven confirmed hypoglycemic episodes were reported in two patients in the liraglutide group, and two episodes in two patients in the additional OAD group. Only one nocturnal confirmed hypoglycemic episode was reported (in the liraglutide group), and there were no recorded severe hypoglycemic episodes in the present trial.

Estimated mean changes from baseline to week 52 in systolic and diastolic blood pressure were −4.00 mmHg and −1.44 mmHg in the liraglutide group, and −3.91 mmHg and −1.64 mmHg in the additional OAD group, respectively. Estimated between‐group differences were small and not statistically significant \[systolic blood pressure −0.10 mmHg (95% CI −2.54, 2.35; *P *= 0.9384); diastolic blood pressure 0.20 mmHg (95% CI −1.55, 1.95; *P* = 0.8246)\]. With regard to pulse rates, there were estimated mean increases from baseline to week 52 of 6.2 and 2.4 b.p.m. in the liraglutide and additional OAD groups, respectively; the estimated mean treatment difference between groups was 3.8 b.p.m. (95% CI 1.9, 5.8; *P* = 0.0001). No apparent developments in electrocardiography were noted.

Efficacy {#jdi12367-sec-0014}
--------

After 52 weeks of treatment, the observed mean (standard deviation) HbA1c was 6.8% (1.0%) with liraglutide and 7.1% (0.8%) with additional OAD (last observation carried forward imputed data). A significantly greater mean reduction in HbA1c was observed in the liraglutide group (−1.21%) than in the additional OAD group (−0.94%; Figure [2](#jdi12367-fig-0002){ref-type="fig"}; Table [3](#jdi12367-tbl-0003){ref-type="table-wrap"}). The estimated mean treatment difference was −0.27% (95% CI −0.44, −0.09; *P* = 0.0026) in favor of liraglutide.

###### 

Summary of efficacy end‐points

  End‐point (52 weeks)                                                           Liraglutide (*n* = 240)   Additional OAD (*n* = 120)   Treatment comparison (95% CI)                                  *P*‐value
  ------------------------------------------------------------------------------ ------------------------- ---------------------------- -------------------------------------------------------------- -----------
  Change in HbA1c (%)                                                            −1.21                     −0.94                        −0.27 (−0.44, −0.09)[‡](#jdi12367-note-0004){ref-type="fn"}    0.0026
  Patients achieving HbA1c \<7.0% (%)                                            67.6                      44.8                         2.57 (1.54, 4.28)[§](#jdi12367-note-0004){ref-type="fn"}       0.0003
  Change in FPG (mg/dL)                                                          −27.8                     −22.4                        −5.47 (−10.83, −0.10)[‡](#jdi12367-note-0004){ref-type="fn"}   0.0458
  Change in mean plasma glucose[†](#jdi12367-note-0004){ref-type="fn"} (mg/dL)   −40.6                     −30.8                        −9.8 (−16.9, −2.8)[‡](#jdi12367-note-0004){ref-type="fn"}      0.0066
  HOMA‐B (%)                                                                     45.24                     35.28                        1.28 (1.16, 1.42)[¶](#jdi12367-note-0004){ref-type="fn"}       \<0.0001
  Proinsulin:insulin ratio (%)                                                   31.36                     37.92                        0.83 (0.74, 0.92)[¶](#jdi12367-note-0004){ref-type="fn"}       0.0006
  Proinsulin:C‐peptide ratio                                                     0.024                     0.030                        0.813 (0.742, 0.892)[¶](#jdi12367-note-0004){ref-type="fn"}    \<0.0001
  Change in bodyweight (kg)                                                      −0.85                     −0.50                        −0.35 (−0.99, 0.29)[‡](#jdi12367-note-0004){ref-type="fn"}     0.2766

CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; HOMA‐B, homeostasis model assessment B; OAD, oral antidiabetic drug. †Seven‐point self‐measured plasma glucose. Treatment comparison values are: ‡estimated treatment difference; §estimated odds ratio; ¶estimated treatment ratio.

John Wiley & Sons, Ltd

![Mean glycosylated hemoglobin by treatment week (full analysis set). Last observation carried forward imputed data. HbA1c, glycosylated hemoglobin; OAD, oral antidiabetic drug.](JDI-7-076-g002){#jdi12367-fig-0002}

In a logistic regression model, the estimated proportion of patients achieving HbA1c \<7.0% at 52 weeks was 67.6% in the liraglutide group and 44.8% in the additional OAD group (Table [3](#jdi12367-tbl-0003){ref-type="table-wrap"}). The proportion of patients achieving this target was statistically significantly higher in the liraglutide group \[estimated odds ratio 2.57 (95% CI 1.54, 4.28; *P* = 0.0003)\].

After 52 weeks of treatment, the observed mean FPG level (standard deviation) was 129 mg/dL \[30 mg/dL; 7.17 mmol/L (1.68 mmol/L)\] in the liraglutide group and 138 mg/dL \[28 mg/dL; 7.63 mmol/L (1.58 mmol/L)\] in the additional OAD group. The reduction from baseline was greater with liraglutide \[−27.8 mg/dL (−1.55 mmol/L)\] than with additional OAD \[−22.4 mg/dL (−1.24 mmol/L); Table [3](#jdi12367-tbl-0003){ref-type="table-wrap"}\]; the estimated mean treatment difference was −5.47 mg/dL (−0.30 mmol/L; 95% CI −10.83, −0.10; *P* = 0.0458).

According to measurements of seven‐point SMPGs, converted from SMBG, the estimated mean treatment difference in mean glucose was −9.8 mg/dL (−0.55 mmol/L; 95% CI −16.9, −2.8; *P* = 0.0066) for the liraglutide group compared with the additional OAD group (Table [3](#jdi12367-tbl-0003){ref-type="table-wrap"}). No significant difference was identified between liraglutide and additional OAD in terms of mean prandial increment in SMPG values across all meals, with an estimated mean treatment difference (liraglutide minus additional OAD) of 1.9 mg/dL (0.11 mmol/L; 95% CI −4.8, 8.7; *P* = 0.5768).

After 52 weeks of treatment, patients in the liraglutide group had significantly higher HOMA‐B \[estimated treatment ratio 1.28 (95% CI 1.16, 1.42; *P* \< 0.0001)\], lower proinsulin:insulin ratio \[estimated treatment ratio 0.83 (95% CI 0.74, 0.92; *P* = 0.0006)\] and lower proinsulin:C‐peptide ratio \[estimated treatment ratio 0.813 (95% CI 0.742, 0.892; *P* \< 0.0001)\] compared with the additional OAD group (Table [3](#jdi12367-tbl-0003){ref-type="table-wrap"}).

Patients in both groups experienced small estimated weight losses at week 52 (liraglutide −0.85 kg; additional OAD −0.50 kg). There was no significant difference between the groups \[estimated mean treatment difference −0.35 kg (95% CI −0.99, 0.29; *P* = 0.2766); Table [3](#jdi12367-tbl-0003){ref-type="table-wrap"}\]. The small weight loss observed in this study might be a result of a lower baseline body mass index (25 vs 30--35 kg/m^2^ in non‐Japanese patients enrolled in international trials).

Discussion {#jdi12367-sec-0015}
==========

This was a 52‐week, open‐label, randomized, parallel‐group trial with an active control (combination therapy with two OADs) to evaluate the safety and efficacy of liraglutide in addition to an OAD in Japanese patients with type 2 diabetes inadequately controlled with one OAD. The primary objective was to evaluate the safety of once‐daily liraglutide (0.9 mg/day) in combination with an OAD (either glinide, metformin, α‐glucosidase inhibitor or thiazolidinedione). In general, liraglutide was well tolerated, and no new safety signals were identified. Furthermore, the safety profile for liraglutide was consistent with previous findings from international trials, including those carried out in Japan, in which liraglutide was studied as a monotherapy[8](#jdi12367-bib-0008){ref-type="ref"}, [17](#jdi12367-bib-0017){ref-type="ref"}, or in combination with metformin[7](#jdi12367-bib-0007){ref-type="ref"}, [24](#jdi12367-bib-0024){ref-type="ref"}, a SU[6](#jdi12367-bib-0006){ref-type="ref"}, [15](#jdi12367-bib-0015){ref-type="ref"}, metformin, a SU or both[11](#jdi12367-bib-0011){ref-type="ref"}, metformin plus thiazolidinedione[9](#jdi12367-bib-0009){ref-type="ref"}, or metformin plus an SU[10](#jdi12367-bib-0010){ref-type="ref"}.

Gastrointestinal effects are commonly reported during treatment with GLP‐1 receptor agonists, particularly in the treatment initiation period[25](#jdi12367-bib-0025){ref-type="ref"}. In the present study, gastrointestinal AEs were reported in both treatment groups, but the occurrence was higher with liraglutide than with additional OAD. However, the difference was mostly because of greater numbers of gastrointestinal AEs during the first 4 weeks of treatment. Stepwise dose escalation was applied to mitigate this issue, in accordance with the usual administration of liraglutide.

Mean amylase and lipase values were slightly increased in the liraglutide group by week 52. However, the increases observed were consistent with previous findings[26](#jdi12367-bib-0026){ref-type="ref"}, and mean values at week 52 were within the reference ranges and thus not considered clinically relevant. No pancreatitis events were identified.

In the present study, rates of confirmed hypoglycemic episodes were low in both groups. The mechanism of action of liraglutide is glucose‐dependent, and hence rates of hypoglycemia are typically much lower than with, for example, SUs[25](#jdi12367-bib-0025){ref-type="ref"}, [27](#jdi12367-bib-0027){ref-type="ref"}.

Liraglutide in combination with an OAD was found to improve glycemic control more effectively than the combination of two OADs. A statistically significantly greater reduction in HbA1c was observed in the liraglutide group than in the additional OAD group. The FPG and SMPG profiles supported this finding.

Although the HbA1c reduction with liraglutide was clinically relevant, relatively low mean baseline HbA1c values (8.1% in both groups) might explain the modest treatment difference in HbA1c (0.27% in favor of liraglutide). Furthermore, more patients in the liraglutide group achieved the HbA1c target of \<7.0%. Considering the small increase in mean HbA1c level in the liraglutide group compared with the additional OAD group during the second half of the trial period (Figure [2](#jdi12367-fig-0002){ref-type="fig"}), the management of patients who had achieved the HbA1c target possibly became less aggressive (e.g., to reduce the risk of hypoglycemia with the pretrial OAD); however, there are no data to confirm this.

The reductions in HbA1c with liraglutide seen in the present study were relative to an additional OAD group receiving various different comparator compounds. However, direct comparisons from other trials have shown that liraglutide significantly reduces HbA1c relative to SUs (as monotherapy)[8](#jdi12367-bib-0008){ref-type="ref"}, [17](#jdi12367-bib-0017){ref-type="ref"}, sitagliptin (as an add‐on to metformin)[24](#jdi12367-bib-0024){ref-type="ref"}, rosiglitazone (as an add‐on to SU)[6](#jdi12367-bib-0006){ref-type="ref"} and exenatide (as an add‐on to metformin, SU or both)[11](#jdi12367-bib-0011){ref-type="ref"}. The greater effect of liraglutide, compared with other therapies, on HbA1c levels could relate to its broad physiological effects, including stimulation of insulin secretion and reduction of glucagon secretion. Although the maximum dose of liraglutide in Japan (0.9 mg/day) is half that in Europe and the USA (1.8 mg/day), the efficacy observed in the present study was comparable with that seen in trials carried out in the West.

Furthermore, measures of β‐cell function were improved in the liraglutide group relative to the additional OAD group. This is consistent with previous findings from a phase 3 study of liraglutide in combination with a SU in Japanese patients[18](#jdi12367-bib-0018){ref-type="ref"}. Similarly, in animal models, GLP‐1 and GLP‐1 receptor agonists have been shown to preserve or even improve β‐cell function[28](#jdi12367-bib-0028){ref-type="ref"}, [29](#jdi12367-bib-0029){ref-type="ref"}, [30](#jdi12367-bib-0030){ref-type="ref"}, [31](#jdi12367-bib-0031){ref-type="ref"}, [32](#jdi12367-bib-0032){ref-type="ref"}. However, further investigation will be required to elucidate the clinical importance of this observation.

There were some limitations to the present work. For practical and ethical reasons, an open‐label design was chosen, which meant that treatment was not blinded. The study lasted for 52 weeks, and hence the durability of the results beyond that time in Japanese patients is not known. Furthermore, there might be selection bias in patients who volunteer for a study, particularly one that involves an injectable drug; this should be considered when generalizing these results to a larger/different population. Finally, data from the present study cannot be extrapolated to young patients (\<20 years‐of‐age) because these were excluded from the trial.

We conclude that the data in Japanese patients (liraglutide 0.9 mg/day) support those reported in other nationalities and ethnicities in finding that liraglutide is well tolerated and effective as combination therapy with an OAD in patients with type 2 diabetes. Reductions in HbA1c were significantly greater with liraglutide than with two OADs in combination. Overall, the data suggest that liraglutide plus an OAD might be more effective than a combination of two OADs in Japanese patients with type 2 diabetes, with a safety profile consistent with previous findings.
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